The Correlation Between Low-Dose Radiotherapy Area of the Mediastinum and CD8+T Cells and the Efficacy of Radiotherapy for Non-Small Cell Lung Cancer

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Shevtsov M, Sato H, Multhoff G, Shibata A. Novel approaches to improve the efficacy of immuno-radiotherapy. Front Oncol. 2019;9:156. doi:10.3389/fonc.2019.00156
   PubMed Web of Science ®Google Scholar
• Jarosz-Biej M, Smolarczyk R, Cichon T, Kulach N. Tumor microenvironment as a “game changer” in cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212. doi:10.3390/ijms20133212
   PubMed Web of Science ®Google Scholar
• Sage EK, Schmid TE, Sedelmayr M, et al. Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. Radiother Oncol. 2016;118(1):176–180. doi:10.1016/j.radonc.2015.11.016
   PubMed Web of Science ®Google Scholar
• Sage EK, Schmid TE, Geinitz H, et al. Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients. Strahlenther Onkol. 2017;193(8):648–655. doi:10.1007/s00066-017-1144-7
   PubMed Web of Science ®Google Scholar
• Grassberger C, Hong TS, Hato T, et al. Differential association between circulating lymphocyte populations with outcome after radiation therapy in subtypes of liver cancer. Int J Radiat Oncol Biol Phys. 2018;101(5):1222–1225. doi:10.1016/j.ijrobp.2018.04.026
   PubMed Web of Science ®Google Scholar
• Tao CJ, Chen YY, Jiang F, et al. A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy. Oncotarget. 2016;7(29).
   Google Scholar
• Hao J, Li M, Zhang T, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes Differs Depending on Lymphocyte Subsets in Esophageal Squamous Cell Carcinoma: an Updated Meta-Analysis. Front Oncol. 2020;10:614. doi:10.3389/fonc.2020.00614
   PubMed Web of Science ®Google Scholar
• Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85. doi:10.3322/caac.21358
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thora Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.009
   PubMed Web of Science ®Google Scholar
• Venkatesulu B, Giridhar P, Pujari L, et al. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): a systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol. 2022;177:81–94. doi:10.1016/j.radonc.2022.10.019
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):247.
   Web of Science ®Google Scholar
• Liu C, Hu Q, Hu K, et al. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer. J Transl Med. 2019;17(1). doi:10.1186/s12967-019-1872-9
   Google Scholar
• Lissoni P, Meregalli S, Bonetto E, et al. Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms. J Biol Regul Homeost Agents. 2005;19(3–4):153–158.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang H, Wu J, et al. Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: immunologic relevance. Radiother Oncol. 2019;131:52–59. doi:10.1016/j.radonc.2018.12.001
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Fang P, Xu C, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018;128(1):154–160. doi:10.1016/j.radonc.2017.11.028
   PubMed Web of Science ®Google Scholar
• Fang P, Jiang W, Davuluri R, et al. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol. 2018;128(3):584–590. doi:10.1016/j.radonc.2018.02.025
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ellsworth S, Campian J, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J National Compr Cancer Network. 2015;13(10):1225–1231. doi:10.6004/jnccn.2015.0151
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clini Cancer Res. 2011;17(16):5473. doi:10.1158/1078-0432.CCR-11-0774
   PubMed Web of Science ®Google Scholar
• Jing W, Xu T, Wu L, et al. Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022;3(9):100391. doi:10.1016/j.jtocrr.2022.100391
   PubMedGoogle Scholar
• Liu Q, Zhao C, Jiang P, Liu D. Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy. Medicine. 2021;100:29.
   Web of Science ®Google Scholar
• Tang C, Welsh JW, De Groot P, et al. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23(6):1388–1396. doi:10.1158/1078-0432.CCR-16-1432
   PubMed Web of Science ®Google Scholar
• Yang ZR, Zhao N, Meng J, et al. Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes. Oncotarget. 2016;7(18):26422–26435. doi:10.18632/oncotarget.8389
   PubMedGoogle Scholar
• Blair TC, Bambina S, Alice AF, et al. Dendritic cell maturation defines immunological responsiveness of tumors to radiation therapy. J Immunol. 2020;204(12):3416–3424. doi:10.4049/jimmunol.2000194
   PubMed Web of Science ®Google Scholar
• Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett. 2007;108(1):45–51. doi:10.1016/j.imlet.2006.10.009
   PubMed Web of Science ®Google Scholar
• Yin L, Xue J, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2020;108(1):212–224. doi:10.1016/j.ijrobp.2020.05.002
   PubMed Web of Science ®Google Scholar
• Barsoumian HB, Ramapriyan R, Younes AI, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020;8(2):e000537. doi:10.1136/jitc-2020-000537
   PubMed Web of Science ®Google Scholar
• Heylmann D, Rodel F, Kindler T, Kaina B. Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells. Biochim Biophys Acta. 2014;1846(1):121–129. doi:10.1016/j.bbcan.2014.04.009
   PubMed Web of Science ®Google Scholar
• Smith HG, Mansfield D, Roulstone V, et al. PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma. Clin Cancer Res. 2019;25(11):3443–3454. doi:10.1158/1078-0432.CCR-18-3767
   PubMed Web of Science ®Google Scholar
• Cheda A, Wrembel-Wargocka J, Lisiak E, Nowosielska EM, Marciniak M, Janiak MK. Single low doses of X rays inhibit the development of experimental tumor metastases and trigger the activities of NK cells in mice. Radiat Res. 2004;161(3):335–340. doi:10.1667/RR3123
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Shirato H, Hosokawa M, et al. The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumor-bearing rats. Radiat Res. 1999;151(6):717. doi:10.2307/3580211
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28(28):4324–4332. doi:10.1200/JCO.2010.28.9793
   PubMed Web of Science ®Google Scholar
• Contreras JA, Lin AJ, Ashley W, et al. Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2018;128(3):498–504. doi:10.1016/j.radonc.2018.05.017
   PubMed Web of Science ®Google Scholar
• Joseph N, Mcwilliam A, Kennedy J, et al. Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. Radiother Oncol. 2019;135:115–119. doi:10.1016/j.radonc.2019.03.008
   PubMed Web of Science ®Google Scholar
• Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response. J Immunol Res. 2016;2016:1–14. doi:10.1155/2016/8941260
   Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Arina A, Beckett M, Fernandez C, Zheng W. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019;10(1). doi:10.1038/s41467-019-11906-2
   PubMedGoogle Scholar